Related Experiment Video
Updated: Feb 17, 2026
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
The Association of Peak Glycemia and No-Reflow Phenomenon in Patients Undergoing Primary Percutaneous Coronary
Golrokh Ghaffari1, Maryam Mehrpooya1, Mohsen Faghihinia1
1Cardiology Department, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran, tums.ac.ir.
Insights
High peak blood glucose levels significantly increase the risk of no-reflow in ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PPCI). Monitoring glucose is crucial for improving outcomes.
Area of Science:
- Cardiology
- Endocrinology
- Medical Research
Background:
- The no-reflow phenomenon is a complication in ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PPCI).
- Elevated blood glucose (BG) levels are common in STEMI patients and may influence cardiovascular outcomes.
Purpose of the Study:
- To investigate the association between peak glycemia and the incidence of no-reflow in STEMI patients treated with PPCI.
- To determine if elevated BG levels independently predict no-reflow in this patient population.
Main Methods:
- A cohort of 252 STEMI patients undergoing PPCI was studied.
- Blood glucose was monitored every 6 hours for 24 hours post-admission to determine peak glycemic levels.
- No-reflow was defined as a corrected TIMI frame count (CTFC) less than 27.
Main Results:
- 42.4% of patients experienced no-reflow, associated with diabetes, peak glycemia, smoking, and high LDL cholesterol.
- Peak glycemia above 180 mg/dL independently increased the odds of no-reflow (OR = 8.16, p < 0.001).
Conclusions:
- Peak glycemia is a significant independent predictor of no-reflow in STEMI patients undergoing PPCI.
- Close monitoring of BG levels and a multidisciplinary approach are essential for managing no-reflow risk, irrespective of diabetic status.
Objective:
This study investigates the effect of peak glycemia on the no-reflow phenomenon in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI) to examine the relationship between elevated blood glucose (BG) levels and no-reflow.
Method:
A total of 252 STEMI patients (81.7% male) who underwent PPCI were enrolled. BG was measured by a glucometer every 6 h for 24 h, starting at the time of patient admission. The maximum measured BG was considered the peak glycemic level. A corrected TIMI frame count (CTFC) of less than 27 was used to define the no-reflow phenomenon in this study.
Results:
42.4% of participants experienced no flow, with a significant association between this condition and diabetes mellitus, peak glycemia, smoking history, and elevated LDL cholesterol levels. Specifically, peak glycemia levels above 180 mg/dL independently increased the odds of no-reflow occurrence (OR = 8.16, 95% CI = 4.1-16.2, p < 0.001).
Conclusion:
The importance of monitoring BG levels in STEMI patients, as well as the critical role of a multidisciplinary approach, regardless of diabetic status, in mitigating the risk of no-reflow and improving clinical outcomes, should be highlighted.
More Related Videos
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
09:23Confirmation of Myocardial Ischemia and Reperfusion Injury in Mice Using Surface Pad Electrocardiography
Published on: November 24, 2016
Related Concept Videos
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:30Acute Coronary Syndrome I: Introduction